PharmaCyte Biotech, Inc. - Recent Material Event

Item 2.01, the Nuvilex and ASPL shares are held in escrow until the completion of Nuvilex’s financing obligations under the Agreement. The Asset Purchase Agreement requires that Nuvilex provide operating capital to ASPL in the amount of $2.5 million on or before December 31, 2012, unless extended by the parties, together with monthly maintenance payments of $60,000 until the $2.5 million operating capital is fully funded.  In the event Nuvilex is unable to provide the ongoing operating capital, or fund the monthly maintenance payments, then Nuvilex would be given credit for amounts paid in the form of a percentage of ownership of ASPL.


ITEM 3.02

UNREGISTERED SALES OF EQUITY SECURITIES


In connection with the Asset Purchase Agreement mentioned in Item 2.01, the Company issued 100,000,000 shares of unregistered, restricted common stock to the owners of Austrianova Singapore Pte. Ltd.  The shares were issued under Rule 144 of the Securities Act of 1933.


ITEM 9.01

 FINANCIAL STATEMENTS AND EXHIBITS.

 

 

 

 

Exhibit No.

Document

 

Location

2.1

2.1.1

2.1.2

2.1.3

2.1.4

Asset Purchase Agreement

Asset Purchase Agreement Addendum, Number 1

Asset Purchase Agreement Addendum, Number 2

Share Certificate

Certificate of Stamp Duty

 

Filed herewith

Filed herewith

Filed herewith

Filed herewith

Filed herewith




2


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


NUVILEX, INC.

(Registrant)


Date: June 27, 2012


/s/ Robert F. Ryan

Robert F. Ryan, M.S., Ph.D.

Chief Executive Officer



 

 


 

 

 

 

3